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The clinical course following intravenous metallic mercury is unknown and ideal
management has notbeen defined. The effectsofa bolus doseseemtovaryfrom
the inconsequential to the rapidly fatal.
CASEREPORT. A previously healthy twenty-six year old woman presented to
casualty about one hour after self - injection with metallic mercury using her
boyfriend's insulin syringe. Themercuryhadbeentakenfromanoldthermometer
in an attempt at suicide following an argument. She smoked 20 cigarettes a day;
there was no previous medical history. On examination therewas some localised
inflammation in the right ante-cubital fossa and mercury was palpable
subcutaneously. There were no other abnormal physical findings. Radiological
examination of the chest and the ante-cubital fossa confirmed the presence of
mercury in the forearm veins and in the pulmonary vasculature ( Figs. I and 2).
Fig 1. X-Ray of arm showing
metallic mercury in the
antecubital fossa and venous
drainage.
Fig2. Multiplemetallicdensities
are seen in the distribution of
the pulmonary vascular bed.
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Shewascommencedonintramusculardimercaprolfor 1 1 daysfollowedbyatwo
yearcourseofitsoralanaloguedimercaptopropane- I -sulfonate (DMPS). During
the second week she was treated with oral penicillamine. Ten days after
admission much of the mercury remaining in her forearm was surgically
removed. Two years after treatment with DMPS had been commenced, it was
discontinued at her request as she found it inconvenient and was not convinced
it was of any continuing benefit.
Throughout the three year follow-up she remained asymptomatic. Blood gases
on admission showed a partial pressure of oxygen(PaO2) of 104 mmHg, which
deteriorated after four days to 85 mmHg but subsequently returned to normal.
Pulmonary function tests were performed after 17 days: forced expiratory
volume in one second was 122% predicted, forced vital capacity 122% predicted
residual volume 51% predicted and total lung capacity 96% predicted. Transfer
factor was 72% predicted by the single breath technique and when corrected for
lung volume 94% predicted. These improved after one month when transfer
factor was 81% predicted and 100% predicted when corrected for lung volume.
Forty months after presentation transfer factor was 85% predicted and when
corrected for lung volume 95% predicted. Chest x-ray remained unchanged
throughout the clinical course.
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Fig 3. Graph to show changes in serum and urinary mercury levels. Serum mercury (black line)
showed a rapid initial fall, urinary mercury (grey line) a transient rise on treatment. Both remain
consideratby elevated above normal after three years.
Full blood picture, liver, renal and thyroid function tests have remained within
normal limits. Serum and urinary mercury levels have been monitored over the
three year follow-up. Blood mercury levels which were initially 1000 nmol/I fell
to300-400 nmol/l [normal lessthan25nmol/l] afteradministration ofDMPSand
have remained at that level following the discontinuation of this treatment.
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Urinarycollectionsformercuryhavebeenlessconsistentbutrosefrom300 nmol/
day to nearly 13,000 nmol/day when DMPS was commenced. Urinary excretion
fell to around 3,000 nmol/day within a few weeks and has remained fairly
constant in spiteofstopping the DMPS. Normal urinary mercury excretion is less
than 100 nmol/day (Fig. 3).
DISCUSSION
Giobetti etal.' reviewed 24 previously published reports of intravenous injection
of metallic mercury which included ten cardiac catheterisation accidents. At
least 12ofthepatientswhowerefollowedupremainedasymptomaticthroughout.
Two cardiac catheter accidents were complicated by neurological signs and
symptoms which were consistent with systemic emboli. Two further patients
developed sepsis and one died. Seven patients reported pleuritic chest pain but
only four complained of dyspnoea. Abnormal pulmonary function tests and
blood gases were much more common than symptoms but most seemed to
resolve. Five patients had evidence ofrenal disease, varying from proteinuria to
a decline in the creatinine clearance and elevation of urea. Treatment of these
patients for mercury toxicity was not documented.
Ambre etal.2reported the caseofa 31 yearold man whowas notedtobe hypoxic
(PaO2 77 mmHg) following lml intravenous metallic mercury. His PaO2 was
92 mmHg after four days. He had no respiratory symptoms and remained well
after one year. Hannigan3 reported a reduction in transferfactor in a patientwho
presented six months after intravenous metallic mercury injection. Celli and
Khan4 noted a restrictive pattern of lung function which resolved within a week
of a 20 ml intravenous injection of metallic mercury. This patient had mercury
inhisabdominalvasculature. Chitkara etal.5documentedanotherasymptomatic
case who also had mercury in his abdominal vasculature. Mercury is thought to
pass through shunts or pulmonary capillaries to aggregate in the left ventricle
where it may embolise into the systemic circulation6. Two further cases were
asymptomatic for one year after injection, although one was hypoxic initially7.
Murray and Hedgepath8 reported a complicated case where the course was
rapidly downward, leading to death within a few weeks, in spite of dimercaprol
therapy. The major problems included acute tubular necrosis, pleural effusions
and septic shock. Other documented effects of intravenous mercury include
urticaria, stomatitis, gingivitis, gingival hypertrophy, abdominal pain and
diarrhoea.
Dimercaprol and its oral analogue DMPS are used in treatment ofpoisoning with
heavy metals and mercury salts. In our patient blood mercury levels fell and
urinary excretion increased after treatment but there is no conclusive evidence
of benefit from dimercaprol and the duration of treatment remains arbitrary.
Known side-effects of dimercaprol therapy include hypertension, tachycardia,
nausea, vomiting, lachrymation, sweating, burning sensations, constriction of
the throat and chest, headache, muscle spasm, abdominal pains, tingling ofthe
extremities and pyrexia in children.
Most reported cases of administration of intravenous metallic mercury have
remainedwell. Some patientsdevelopa reduction intransferfactorwhich isoften
asymptomatic and seems to recover. Variable renal and neurological sequelae
have also been documented. Treatment with dimercaprol or another chelating
agent may be of some benefit but the outcome remains variable.
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